Celgene: Fears Are Overplayed

Any company buying back a lot of stock always catches my attention. A stock has to be cheap and the balance sheet strong in order for a company to repurchase a large amount of the outstanding stock. Celgene (CELG) fits the equation after announcing another $3 billion buyback plan while the stock trades at multi-year lows.

Image Source: Celgene website

One-Trick Pony?

The biggest risk to the Celgene story is that the large biotech is mostly a one-trick pony. Flagship multiple myeloma drug, Revlimid, accounts for over 60% of sales. Revilmid sales grew 19% in Q1 to $2.2 billion and nearly equaled total company sales growth of 20%.

The drug pipeline fears were flamed back last October when the company had to terminate the studies assessing GED-0301 (mongersen) in Crohn's disease. Celgene spent an incredible $1.6 billion on the drug and the failure added to some irrational fears that the reliance on Revlimid wouldn't last.

READ FULL ARTICLE HERE